Neuphoria Therapeutics Inc.NEUP
What Neuphoria Therapeutics Inc. does.
Neuphoria Therapeutics Inc. is a Delaware corporation and a clinical-stage biotechnology company. Following the results of our Phase 3 AFFIRM-1 trial and the restructuring actions taken during fiscal 2026, our activities are focused on completing the proposed merger with Scancell Holdings plc ("Scancell"), preserving cash, maintaining our public-company and contractual obligations, and managing our intellectual property and economic interests in partnered programs. We are currently conducting limited active internal research and development activities focused on our alpha7 nicotinic acetylcholine receptor negative allosteric modulator portfolio.
Our lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. On October 20, 2025, we announced that AFFIRM-1, our Phase 3 trial of BNC210 for the acute treatment of social anxiety disorder ("SAD"), did not meet its primary endpoint, and secondary endpoint analysis did not show statistically significant differences or improvement over placebo. We discontinued the BNC210 SAD program and did not initiate the planned AFFIRM-2 trial. We subsequently maintained clinical readiness of the BNC210 program for post-traumatic stress disorder ("PTSD") but paused the planned SYMPHONY Phase 2b/3 trial pending the strategic transaction review process and subsequent planned merger transaction with Scancell.
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $15.6M | $1.2M |
| Net income | — | — | -$21.4M | -$15.5M | -$369,632 | -$13.5M |
More on NEUP.
- Neuphoria Therapeutics Inc. summary
- Neuphoria Therapeutics Inc. financial statements
- Neuphoria Therapeutics Inc. key metrics
- Neuphoria Therapeutics Inc. health scores and style box
- Neuphoria Therapeutics Inc. earnings
- Neuphoria Therapeutics Inc. dividends
- Neuphoria Therapeutics Inc. valuation
- Neuphoria Therapeutics Inc. ownership and insiders
- Neuphoria Therapeutics Inc. peers
Figures from Neuphoria Therapeutics Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.